Nippon Shinyaku Co., Ltd.
Nihon Shinyaku Co., Ltd. Q1 Financial Summary (IFRS) (Consolidated) for Fiscal Year Ending 2027
Consolidated revenue for Q1 was 49,066 million yen, up 24.1% YoY. Operating profit was 12,311 million yen, up 23.4% YoY. Net income attributable to owners of the parent was 10,109 million yen, up 22.5% YoY. Full-year guidance unchanged. Segment-wise, Pharmaceuticals contributed 43,256 million yen in revenue and Functional Foods 5,810 million yen. A results briefing is scheduled.
Key Figures
- Revenue: 49,066 million yen (YoY +24.1%)
- Operating profit: 12,311 million yen (YoY +22.1%)
- Net income attributable to owners of the parent: 10,109 million yen (YoY +22.5%)
AI要約
Overview of results
This quarter's revenue was 49,066 million yen, up 24.1% YoY, primarily supported by continued growth in Utarabi, Fintepla, Jaiparka, etc., despite price revisions and generic impact, with contribution from Uptra. Operating profit was 12,311 million yen, up 22.1% YoY; income before tax was 12,959 million yen; quarterly net income was 10,108–10,109 million yen (interim disclosed value is 10,109 million yen, up 22.5% YoY). Pharmaceutical and Functional Foods sales remained solid. Full-year guidance unchanged from prior disclosure.
Outlook and key notes
Supplementary materials for the results are available; a conference call for institutional investors and securities analysts will be held. There are no changes to the full-year business forecast for fiscal year ending March 2027. Segment details: Pharmaceuticals revenue 43,256 million yen, Functional Foods 5,810 million yen. For new drug development, progress in multiple Phase III/PP trials and the impact of license agreements are noted, and future clinical/approval trends may affect results.
Nihon Shinyaku Co., Ltd.
Company overview · Stock price · Financial data · All IR
